{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:30:52Z","timestamp":1790775052045,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T00:00:00Z","timestamp":1573084800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.ahj.2019.10.014","type":"journal-article","created":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T21:33:03Z","timestamp":1572557583000},"page":"70-77","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United States"],"prefix":"10.1016","volume":"219","author":[{"given":"Christopher P.","family":"Cannon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"de Lemos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Rosenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie M.","family":"Ballantyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Yazdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Elliott-Davey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine E.","family":"Mues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail N.","family":"Kosiborod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9753","key":"10.1016\/j.ahj.2019.10.014_bb0005","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.ahj.2019.10.014_bb0010","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ahj.2019.10.014_bb0015","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.ahj.2019.10.014_bb0020","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.ahj.2019.10.014_bb0025","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.ahj.2019.10.014_bb0030","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ahj.2019.10.014_bb0035","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1001\/jama.2014.4030","article-title":"Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial","volume":"311","author":"Robinson","year":"2014","journal-title":"JAMA"},{"issue":"15","key":"10.1016\/j.ahj.2019.10.014_bb0040","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","article-title":"Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: The GAUSS-3 Randomized Clinical Trial","volume":"315","author":"Nissen","year":"2016","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ahj.2019.10.014_bb0045","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","article-title":"Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial","volume":"9","author":"Moriarty","year":"2015","journal-title":"J Clin Lipidol"},{"issue":"9","key":"10.1016\/j.ahj.2019.10.014_bb0050","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1001\/jamacardio.2017.2289","article-title":"Simulation of lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease","volume":"2","author":"Cannon","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"8","key":"10.1016\/j.ahj.2019.10.014_bb0055","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1001\/jamacardio.2017.0911","article-title":"Adherence to high-intensity statins following a myocardial infarction hospitalization among Medicare beneficiaries","volume":"2","author":"Colantonio","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"22","key":"10.1016\/j.ahj.2019.10.014_bb0060","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1016\/j.jacc.2017.03.585","article-title":"Trends in use of high-intensity statin therapy after myocardial infarction, 2011 to 2014","volume":"69","author":"Rosenson","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2019.10.014_bb0065","doi-asserted-by":"crossref","unstructured":"Colantonio LD, Rosenson RS, Deng L, et al. Adherence to statin therapy among US adults between 2007 and 2014. J Am Heart Assoc. 2019;8(1):e010376.","DOI":"10.1161\/JAHA.118.010376"},{"issue":"16","key":"10.1016\/j.ahj.2019.10.014_bb0070","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2019.10.014_bb0075","doi-asserted-by":"crossref","unstructured":"Unni SK, Quek RG, Biskupiak J, Lee VC, Ye X, Gandra SR. Assessment of statin therapy, LDL-C levels, and cardiovascular events among high-risk patients in the United States. J Clin Lipidol. 2016;10(1):63\u201371 e61\u201363.","DOI":"10.1016\/j.jacl.2015.09.008"},{"issue":"5","key":"10.1016\/j.ahj.2019.10.014_bb0080","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jacl.2013.06.002","article-title":"Treatment pattern changes in high-risk patients newly initiated on statin monotherapy in a managed care setting","volume":"7","author":"Simpson","year":"2013","journal-title":"J Clin Lipidol"},{"issue":"4","key":"10.1016\/j.ahj.2019.10.014_bb0085","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/clc.22713","article-title":"PCSK9 inhibitor access barriers-issues and recommendations: Improving the access process for patients, clinicians and payers","volume":"40","author":"Baum","year":"2017","journal-title":"Clin Cardiol"},{"issue":"11","key":"10.1016\/j.ahj.2019.10.014_bb0090","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1001\/jamacardio.2017.3451","article-title":"Association of prior authorization and out-of-pocket costs with patient access to PCSK9 inhibitor therapy","volume":"2","author":"Navar","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"2","key":"10.1016\/j.ahj.2019.10.014_bb0095","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/MJT.0b013e3181b442b9","article-title":"Switching from atorvastatin to simvastatin in patients at high cardiovascular risk: effects on low-density lipoprotein cholesterol","volume":"17","author":"Aronow","year":"2010","journal-title":"Am J Ther"},{"issue":"18","key":"10.1016\/j.ahj.2019.10.014_bb0100","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1517\/14656566.2010.522991","article-title":"To switch (statins) or not to switch? That is the question","volume":"11","author":"Athyros","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ahj.2019.10.014_bb0105","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S1\u201345."},{"issue":"23","key":"10.1016\/j.ahj.2019.10.014_bb0110","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1016\/j.jacc.2011.10.824","volume":"58","author":"Smith","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2019.10.014_bb0115","first-page":"2018","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","author":"Grundy","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.ahj.2019.10.014_bb0120","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.ahj.2015.08.002","article-title":"Design and rationale for the Patient and Provider Assessment of Lipid Management (PALM) registry","volume":"170","author":"Navar","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2019.10.014_bb0125","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ahj.2017.08.005","article-title":"Lipid management in contemporary community practice: Results from the Provider Assessment of Lipid Management (PALM) Registry","volume":"193","author":"Navar","year":"2017","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2019.10.014_bb0130","doi-asserted-by":"crossref","unstructured":"Bradley CK, Wang TY, Li S, et al. Patient-Reported Reasons for Declining or Discontinuing Statin Therapy: Insights From the PALM Registry. J Am Heart Assoc. 2019;8(7):e011765.","DOI":"10.1161\/JAHA.118.011765"},{"issue":"3","key":"10.1016\/j.ahj.2019.10.014_bb0135","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jacc.2014.09.088","article-title":"Underutilization of high-intensity statin therapy after hospitalization for coronary heart disease","volume":"65","author":"Rosenson","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.ahj.2019.10.014_bb0140","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.117.003626","article-title":"Statin discontinuation, reinitiation, and persistence patterns among medicare beneficiaries after myocardial infarction: a cohort study","volume":"10","author":"Booth","year":"2017","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"7","key":"10.1016\/j.ahj.2019.10.014_bb0145","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011378","article-title":"It's not too late to improve statin adherence: association between changes in statin adherence from before to after acute myocardial infarction and all-cause mortality","volume":"8","author":"Hickson","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.ahj.2019.10.014_bb0150","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.amjcard.2014.09.041","article-title":"Gender disparities in evidence-based statin therapy in patients with cardiovascular disease","volume":"115","author":"Virani","year":"2015","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.ahj.2019.10.014_bb0155","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.118.004652","article-title":"Variation in lipid-lowering therapy use in patients with low-density lipoprotein cholesterol >\/=190 mg\/dL: Insights from the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry","volume":"11","author":"Virani","year":"2018","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"16","key":"10.1016\/j.ahj.2019.10.014_bb0160","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.jacc.2018.02.032","article-title":"Sex differences in high-intensity statin use following myocardial infarction in the United States","volume":"71","author":"Peters","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.ahj.2019.10.014_bb0165","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.jacc.2011.02.005","article-title":"Effectiveness-based guidelines for the prevention of cardiovascular disease in women\u20142011 update: a guideline from the American Heart Association","volume":"57","author":"Mosca","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.ahj.2019.10.014_bb0170","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1161\/CIRCOUTCOMES.108.824763","article-title":"Trends in the use of evidence-based treatments for coronary artery disease among women and the elderly: findings from the get with the guidelines quality-improvement program","volume":"2","author":"Lewis","year":"2009","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"7","key":"10.1016\/j.ahj.2019.10.014_bb0175","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1161\/CIRCULATIONAHA.119.041730","article-title":"Use of guideline-recommended risk reduction strategies among patients with diabetes and atherosclerotic cardiovascular disease","volume":"140","author":"Arnold","year":"2019","journal-title":"Circulation"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870319302960?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870319302960?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:03:25Z","timestamp":1757570605000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870319302960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":35,"alternative-id":["S0002870319302960"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2019.10.014","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United States","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2019.10.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}